drugset / Trial / NCT04301154
Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth
Phase 1
Completed
25 enrolled
Henry M. Jackson Foundation for the Advancement of Military Medicine
Armed Forces Research Institute of Medical Sciences, Thailand · collabBambino Gesù Hospital and Research Institute · collabCase Western Reserve University · collabChulalongkorn University · collabJohns Hopkins University · collabKarolinska Institutet · collabLeidos Biomedical Research, Inc. · collabPENTA Foundation · collabUniversity of Miami · collabUniversity of Padova · collabWalter Reed Army Institute of Research (WRAIR) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate the Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens with or without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth
Timeline
- Start
- 2022-02-18
- Primary completion
- 2023-10-16
- Completion
- 2023-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cervarix | Vaccine | 0.5 ml | Intramuscular |
| Subject | HIVIS DNA | Vaccine | 0.5 ml | Intramuscular |
| Subject | HIVIS DNA | Vaccine | 1500 ug | Intramuscular |
| Subject | MVA-CMDR | Vaccine | 1 ml | Intramuscular |